CI vs. VRTX, BSX, BMY, MDT, REGN, SNY, GSK, HCA, GILD, and ELV
Should you be buying The Cigna Group stock or one of its competitors? The main competitors of The Cigna Group include Vertex Pharmaceuticals (VRTX), Boston Scientific (BSX), Bristol-Myers Squibb (BMY), Medtronic (MDT), Regeneron Pharmaceuticals (REGN), Sanofi (SNY), GSK (GSK), HCA Healthcare (HCA), Gilead Sciences (GILD), and Elevance Health (ELV). These companies are all part of the "medical" sector.
The Cigna Group (NYSE:CI) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, community ranking, profitability, valuation, analyst recommendations, media sentiment and dividends.
The Cigna Group currently has a consensus target price of $362.14, indicating a potential upside of 2.16%. Vertex Pharmaceuticals has a consensus target price of $429.45, indicating a potential upside of 8.04%. Given Vertex Pharmaceuticals' higher probable upside, analysts clearly believe Vertex Pharmaceuticals is more favorable than The Cigna Group.
87.0% of The Cigna Group shares are owned by institutional investors. Comparatively, 91.0% of Vertex Pharmaceuticals shares are owned by institutional investors. 0.6% of The Cigna Group shares are owned by insiders. Comparatively, 0.2% of Vertex Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
In the previous week, The Cigna Group had 4 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 26 mentions for The Cigna Group and 22 mentions for Vertex Pharmaceuticals. Vertex Pharmaceuticals' average media sentiment score of 0.73 beat The Cigna Group's score of 0.65 indicating that Vertex Pharmaceuticals is being referred to more favorably in the news media.
The Cigna Group has a beta of 0.56, meaning that its stock price is 44% less volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.35, meaning that its stock price is 65% less volatile than the S&P 500.
The Cigna Group has higher revenue and earnings than Vertex Pharmaceuticals. The Cigna Group is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Vertex Pharmaceuticals received 622 more outperform votes than The Cigna Group when rated by MarketBeat users. Likewise, 75.65% of users gave Vertex Pharmaceuticals an outperform vote while only 71.82% of users gave The Cigna Group an outperform vote.
Vertex Pharmaceuticals has a net margin of 36.68% compared to The Cigna Group's net margin of 2.64%. Vertex Pharmaceuticals' return on equity of 21.91% beat The Cigna Group's return on equity.
Summary
Vertex Pharmaceuticals beats The Cigna Group on 11 of the 19 factors compared between the two stocks.
Get The Cigna Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for CI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
The Cigna Group Competitors List
Related Companies and Tools
